APA (7th ed.) Citation

MG, Z., O, J., DM, J., JA, Z., RJ, G., V, W., . . . KT, F. (2024). Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U. JCO precision oncology, 8, e2400327. https://doi.org/10.1200/PO.24.00327

Chicago Style (17th ed.) Citation

MG, Zauderer, et al. "Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U." JCO Precision Oncology 8 (2024): e2400327. https://doi.org/10.1200/PO.24.00327.

MLA (9th ed.) Citation

MG, Zauderer, et al. "Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U." JCO Precision Oncology, vol. 8, 2024, p. e2400327, https://doi.org/10.1200/PO.24.00327.